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Dear Editor, 
 
Obesity is a medical condition in which excess body fat has accumulated to such an extent 
that it may have an adverse effect on health, leading to reduced life expectancy (Haslam and 
James, 2005). The lifestyle treatments directed at improving diet and physical activity are 
considered as first line treatment for obesity; however, if these fail, antiobesity medication is 
recommended. In the past years, numerous drugs have been approved for the treatment of 
obesity; however, currently, orlistat is the only food and drug administration (FDA) approved 
drug for long term management of obesity (Table 1). 
Lipolytic rate in white adipose tissue (WAT) has been positively and negatively correlated 
with indexes of insulin resistance and WAT de novo lipogenesis gene expression. It is a rea-
sonable hypothesis that the difficulty in mobilizing lipids in adipocytes could contribute to 
increased adiposity and obesity, and thereby reducing the insulin sensitivity (Caminhotto et 
al., 2014). On the contrary, Girousse et al. (2013) has reported a new mechanism for the regu-
lation of insulin sensitivity, who demonstrated that partial inhibition of lipolysis via reduced 
action of hormone sensitive lipase (HSL), either by genetic modification or by pharmacologi-
cal inhibition, reshapes the fatty acid fluxes without increase of fat mass; improving glucose 
metabolism through cell-autonomous induction of fat cell de novo lipogenesis and leading to 
improved insulin sensitivity in mice. Orlistat is a well-known inhibitor of pancreatic lipase 
(PL) that is also reported to inhibit HSL; thus inhibiting the stimulated lipolysis (Clifford et 
al., 2000; Bustanji et al., 2010). It is reported that inhibition of HSL improves lipid profile 
while reduces plasma glucose (Claus et al., 2005). In this context, inhibition of lipolysis with 
orlistat provides a mechanism for the decrease plasma free fatty acids (FFA) and improve-
ment in insulin sensitivity. Hence, the control of metabolic activity in WAT stands out as an 
important therapeutic intervention in the treatment of metabolic diseases (Caminhotto et al., 
2014). 
Enç et al. (2009) reported that orlistat accelerates gastric emptying and attenuates gastric 
inhibitory peptide (GIP) release in healthy subjects; that play an important role in the modula-
tion of lipid metabolism, obesity and insulin resistance. GIP, an insulinotropic hormone, is 
secreted from enteroendocrine upper gut K-cells postprandially. GIP similar to the incretin 
effect of glucagon-like peptide-1 (GLP-1), stimulates glucose-dependent insulin secretion. By 
acting on GIP receptors on adipocytes, GIP exhibits insulin mimetic properties such as eleva-
tion in glucose uptake, fatty acid synthesis, lipoprotein lipase synthesis, and reduction in glu-
EXCLI Journal 2015;14:290-293 – ISSN 1611-2156 
Received: December 22, 2014, accepted: January 31, 2015, published: February 20, 2015 
 
 
291 
cagon-induced lipolysis; resulting in fat accumulation in adipocytes, obesity and insulin re-
sistance.  
Apart from decreasing insulin resistance, orlistat is reported to increase postprandial GLP-
1 levels; thereby enhancing the insulin sensitivity and blunting the postprandial rise in blood 
glucose in type 2 diabetic patients. Hence, increased GLP-1 levels, which lead to decreased 
food intake, may also contribute to the weight loss that is associated with the use of orlistat 
(Damci et al., 2004). Elevated anorectic gut hormones, such as GLP-1 and peptide YY 
(PYY), play a crucial role in the reduction in food intake. The long-term inhibition of intesti-
nal lipase by orlistat increases the pre-prandial levels of GLP-1 and PYY, independent of 
body mass changes. Therefore, long-term treatment with orlistat may exert hunger suppress-
ing and insulin sensitizing incretin effect beyond the weight reduction (Olszanecka-
Glinianowicz et al., 2013). 
Blood glucose control becomes increasingly challenging in the obese patient with type 2 
diabetes after the failure of metformin monotherapy (Scheen, 2003; Niswender, 2010). Mod-
erate weight loss is recommended in these patients, with the conjunctive use of weight loss 
medications. Orlistat is reported to be as effective as metformin in reducing body weight and 
insulin resistance in obese patients (Sari et al., 2004). As per earlier reports, a moderate 
weight loss with orlistat treatment resulted in greater improvement in FFA levels and insulin 
sensitivity in type 2 diabetics (Derosa et al., 2012; Olszanecka-Glinianowicz et al., 2013) as 
well as obese subjects (Tiikkainen et al., 2004; Derosa et al., 2010).  
With respect to the future prospects point of view, obesity is set to be the world’s major 
cause of morbidity and mortality in the 21st Century. The year 2013 was a landmark for the 
field of obesity, as in June 2013, the American Medical Association recognizes obesity as a 
disease (AMA, 2013). The worldwide obesity prevalence continues to increase with a grow-
ing demand for effective and safe antiobesity drugs. In the last few years, despite promising 
results on reduction of body weight, many antiobesity drugs were withdrawn from the market 
due to serious adverse effects (Kang and Park, 2012). Currently, orlistat is the only FDA ap-
proved drug for long term management of obesity. Therefore, there is need for development 
of more effective and safe antiobesity drugs. Additionally, a lifestyle modification such as di-
et and exercise need to be focused as a positive approach for treatments for obesity as it re-
mains the cornerstone in the management of obesity.  
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Table 1: Antiobesity drugs and their current status (Elangbam, 2009; Ioannides-Demos et al., 2011; Kang and Park, 2012) 
Drug Mechanism of action Status Adverse effects 
Dinitrophenol Increases metabolic rate  Introduced 1933  End of the official clinical use 1938  
Neuropathy, cataract and metabolic collapse 
Amphetamines:  
dexamphetamine, 
methamphetamine 
Norepinephrine (NE), Dopamine (DA) 
and 5-hydroxy tryptamine (5-HT) re-
leaser (appetite suppression) 
 Introduced 1936 
 Desoxyephedrine (FDA approval for 
obesity 1944) for short-term use 
Dependency and abuse potential, cardiovas-
cular adverse eﬀects such as hypertension 
(HT), tachycardia, nervousness and psychosis  
Phenylpropanolamine 
NE, DA and 5-HT releaser (appetite 
suppression) 
 Introduced 1939-US 
 Antiobesity use 1979 
 Withdrawn 2000  
Cardiac arrest, increase risk of hemorrhagic 
stroke (especially women), arrhythmias, myo-
cardial infarction, pulmonary HT 
Diethylpropion  NE releaser, and NE and DA reuptake inhibitor (appetite suppression) 
 Introduced 1959 
 Withdrawn 2000-Europe 
Psychosis, nervousness, insomnia, transient 
ischemic attack and pulmonary HT 
Phentermine 
NE and DA reuptake inhibitor (appetite 
suppression) 
 Introduced 1959-US 
 Withdrawn 2000-Europe 
Insomnia, tremor, increase blood pressure, 
headache and palpitation 
Aminorex 
5-HT releaser and reuptake inhibitor; 
potent monoamine oxidase inhibitor 
(appetite suppression) 
 Introduced 1965-Europe 
 Withdrawn 1968 
Pulmonary HT 
Mazindol 
NE reuptake inhibitor  Introduced 1970 
 Discontinued 1993-Australia 
 Withdrawn 2000-Europe  
Nervousness, atrial fibrillation, insomnia, syn-
cope and pulmonary HT 
Fenfluramine 5HT releaser and reuptake inhibitor (appetite suppression) 
 Introduced 1963-Europe; 1973-US 
 Withdrawn 1997 
Valvular heart disease and pulmonary HT 
Dexfenfluramine 5HT releaser and reuptake Inhibitor (appetite suppression) 
 Introduced 1985-Europe; 1996-US 
 Withdrawn 1997  
Valvular heart disease and pulmonary HT 
Sibutramine Selective serotonin and NE reuptake inhibitor (appetite suppression) 
 Introduced 1997-US; 2001-Europe 
 Withdrawn 2010  
Increased risk of heart attack and stroke in 
high-risk cardiac patients 
Rimonabant 
Selective cannabinoid-1 (CB-1) receptor 
blocker 
 Introduced 2006-Europe 
 Not approved in US due to concern 
over psychiatric side effects 
 Withdrawn 2009  
Potential of serious psychiatric disorders 
Orlistat 
 
Pancreatic lipase inhibitor (decreased 
fat absorption) 
 Introduced 1999-USA 
 Currently, FDA-approved drug for 
long-term obesity management 
Abdominal pain, bloating, flatulence, oily 
stools, diarrhoea and decrease absorption of 
fat soluble vitamins 
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